MMP9 and sarcoma: These data suggest that the in vivo efficacy of ATIQCTPC (0.01 μmol/kg/day for 11 days) effectively inhibiting the metastasis of LLC toward lung could be the result of it decreasing MMP-9 level in the serum and the primary tumor of LLC sarcoma implanted C57BL/6 mice.